Saranas was chosen to participate in the conference’s Cardiovascular Innovations session. The company’s Early Bird™ Bleed Monitoring System is nearing the end of final product testing, and the company expects to file a De Novo submission to the FDA in 2018.

President and CEO Zaffer Syed said, “We are very honored to be chosen to present at this prestigious conference, especially from a highly competitive field.”  Zaffer adds, “It is our belief that our Early Bird Bleed Monitoring System can have an important impact on healthcare costs and reduce the risk of death in patients undergoing endovascular procedures. Presenting at CRT18 gives us the opportunity to discuss how the Early Bird can be integrated into clinical practice.’’

The Early Bird Bleed Monitoring System includes a vascular access sheath embedded with sensors that are designed to detect and monitor bleeding from a blood vessel accidentally ruptured during endovascular procedures, such as a transcatheter aortic valve implantation (TAVI), large bore hemodynamic support device placement, or other complex cardiovascular interventions, where the femoral artery or vein is used to obtain vascular access. The technology was invented at the Texas Heart Institute.